Literature DB >> 25023041

An alternative approach to account for patient organ doses from imaging guidance procedures.

Alan P Nelson1, George X Ding2.   

Abstract

PURPOSE: To investigate the feasibility of an alternative method of accounting for additional organ doses resulting from image guidance procedures during patient treatment planning through tabulated values based on scan protocol and scan site. METHODS AND MATERIALS: Patient-specific imaging dose to 30 patients resulting from Varian OBI kV-CBCT scans using the Standard Head (17 patients), Low-dose Thorax (8 patients), and Pelvic (5 patients) scan protocols were retrospectively calculated using Monte Carlo methods. Dose dependence on scan location and patient geometry was explored. Patient organ doses were analyzed by using dose-volume histograms and expressed by the mean, minimum dose delivered to 50% of the organ volume, D50. The reported doses are dose-to-medium instead of dose-to-water.
RESULTS: The organ doses from all patient-specific calculations show predictable and limited ranges across patients. For brain isocenters using Standard Head Scans: Bone: 0.7-1.1 cGy, Brain: 0.2-0.3 cGy, Brainstem: 0.2-0.3 cGy, Skin: 0.3-0.4 cGy, Eye: 0.03-0.3 cGy. For head and neck patients using the Standard Head Scan: Bone: 0.3-0.6 cGy, Parotids: 0.3-0.4 cGy, Spinal Cord: 0.15-0.25 cGy, Thyroid: 0.1-0.25 cGy, Skin: 0.2-0.3 cGy, Trachea-Esophagus: 0.1-0.2 cGy. For chest using Thorax Scans: Bone: 1.1-1.8 cGy, Soft tissue organs (Bowel, Lung, Heart, Kidney, Esophagus, and Spinal Cord): 0.3-0.6 cGy. For abdominal site using Pelvic Scans: Bone: 3.2-4.2 cGy. Soft tissue organs (Bladder, Bowel, Rectum, Prostate, and Skin) D50s fell between 1.2 and 2.2 cGy. Femoral Heads: 2.5-3.4 cGy.
CONCLUSIONS: It is adequate to estimate and account for organ dose by using tabulated values based on scan procedure and site because organ doses from imaging procedures are only modestly dependent upon scan location and body size. Considering the dose variation and magnitude of dose from each scan protocol in comparison to therapeutic doses, this approach provides a simple alternative to account for additional imaging guidance doses during patient treatment planning. Clinicians can use these tabulated values to make informed decisions in selecting the appropriate imaging procedures and imaging frequency during radiotherapy treatment.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Managing imaging dose; Method of accounting organ dose; kV–CBCT dose

Mesh:

Year:  2014        PMID: 25023041     DOI: 10.1016/j.radonc.2014.05.019

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  4 in total

1.  Dosimetric assessment of the exposure of radiotherapy patients due to cone-beam CT procedures.

Authors:  Mariana Baptista; Salvatore Di Maria; Sandra Vieira; Joana Santos; Joana Pereira; Miguel Pereira; Pedro Vaz
Journal:  Radiat Environ Biophys       Date:  2018-11-03       Impact factor: 1.925

2.  Technical Note: Imaging dose resulting from optimized procedures with limited-angle intrafractional verification system during stereotactic body radiation therapy lung treatment.

Authors:  George X Ding; Yawei Zhang; Lei Ren
Journal:  Med Phys       Date:  2019-04-29       Impact factor: 4.071

3.  Evaluation of Dose Distribution and Normal Tissue Complication Probability of a Combined Dose of Cone-Beam Computed Tomography Imaging with Treatment in Prostate Intensity-Modulated Radiation Therapy.

Authors:  Tetsuya Tomita; Tomonori Isobe; Yoshinobu Furuyama; Hideyuki Takei; Daisuke Kobayashi; Yutaro Mori; Toshiyuki Terunuma; Eisuke Sato; Hiroshi Yokota; Takeji Sakae
Journal:  J Med Phys       Date:  2020-07-20

4.  Contribution of Imaging to Organs at Risk Dose during Lung Stereotactic Body Radiation Therapy.

Authors:  Milovan Savanović; François Gardavaud; Dražan Jaroš; Bénédicte Lonkuta; Matthias Barral; François Henri Cornelis; Jean-Noël Foulquier
Journal:  J Biomed Phys Eng       Date:  2021-04-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.